Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

157.02USD
12:28am IST
Change (% chg)

$-1.02 (-0.65%)
Prev Close
$158.04
Open
$158.38
Day's High
$160.75
Day's Low
$155.46
Volume
66,039
Avg. Vol
213,991
52-wk High
$200.45
52-wk Low
$87.64

Latest Key Developments (Source: Significant Developments)

Capital International Investors Reports 10 Pct Passive Stake In Bluebird Bio Inc
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - bluebird bio Inc ::CAPITAL INTERNATIONAL INVESTORS REPORTS 10.0 PERCENT PASSIVE STAKE IN BLUEBIRD BIO INC AS OF DEC 31, 2018 - SEC FILING.  Full Article

Bluebird Bio And Inhibrx Announce CAR-T Cell Immunotherapy Collaboration
Monday, 7 Jan 2019 

Jan 7 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND INHIBRX ANNOUNCE COLLABORATION TO RESEARCH, DEVELOP AND COMMERCIALIZE CAR T CELL IMMUNOTHERAPIES.BLUEBIRD BIO - INHIBRX WILL PROVIDE BLUEBIRD BIO EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALIZE CERTAIN CELL THERAPY PRODUCTS.BLUEBIRD BIO INC - INHIBRX RECEIVED A $7.0 MILLION UPFRONT PAYMENT.  Full Article

Regeneron & Bluebird Bio To Collaborate To Develop New Cell Therapies For Cancer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - bluebird bio Inc ::REGENERON AND BLUEBIRD BIO ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NEW CELL THERAPIES FOR CANCER.REGENERON PHARMACEUTICALS INC - WILL ALSO MAKE A $100 MILLION INVESTMENT IN BLUEBIRD BIO COMMON STOCK AT A PRICE OF $238.10 PER SHARE.REGENERON PHARMACEUTICALS - CO, BLUEBIRD BIO SELECTED 6 INITIAL TARGETS, WILL EQUALLY SHARE COSTS OF RESEARCH AND DEVELOPMENT UP TO POINT OF SUBMITTING IND APPLICATION.  Full Article

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NEW CELL THERAPIES FOR CANCER.BLUEBIRD BIO - CO, REGENERON WILL SPECIFICALLY LEVERAGE REGENERON'S VELOCISUITE PLATFORM TECHNOLOGIES FOR DISCOVERY OF FULLY HUMAN ANTIBODIES.BLUEBIRD BIO - CO, REGENERON HAVE SELECTED 6 TARGETS & WILL EQUALLY SHARE COSTS OF RND UP TO POINT OF SUBMITTING AN INVESTIGATIONAL NEW DRUG APPLICATION.  Full Article

Bluebird Bio Reports Q2 Loss Per Share $2.91
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q2 REVENUE $7.9 MILLION VERSUS I/B/E/S VIEW $9.6 MILLION.ENDED QUARTER WITH $1.46 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.QTRLY LOSS PER SHARE $2.91.Q2 EARNINGS PER SHARE VIEW $-2.35, REVENUE VIEW $9.6 MILLION -- THOMSON REUTERS I/B/E/S.ANTICIPATE FILING FIRST POTENTIAL REGULATORY APPROVAL IN EUROPE WITH LENTIGLOBIN TO TREAT TDT IN H2 2018.  Full Article

Bluebird Bio Announces Public Offering Of 3.4 Mln Shares Priced At $162.50 Per Share
Wednesday, 25 Jul 2018 

July 24 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 3.4 MILLION SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $162.50 PER SHARE.  Full Article

• BLUEBIRD BIO SAYS CELGENE AMENDED PHASE 2 STUDY PROTOCOL
Friday, 13 Jul 2018 

July 12 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO - CO, CELGENE CONTINUE TO ANTICIPATE A POTENTIAL APPROVAL OF BB2121 PRODUCT CANDIDATE IN RELAPSED & REFRACTORY MULTIPLE MYELOMA IN 2020.BLUEBIRD BIO SAYS CELGENE HAS AMENDED STUDY PROTOCOL FOR KARMMA STUDY, AN ONGOING PHASE 2 STUDY OF BB2121 PRODUCT CANDIDATE - SEC FILING.BLUEBIRD BIO - DOSE RANGE FOR KARMMA STUDY WILL BE 150 TO 450 X 10(6)CAR+ T CELLS AND ENROLLMENT WILL INCREASE TO UP TO 140 PATIENTS.BLUEBIRD BIO INC - IN ADDITION, CELGENE HAS AMENDED STUDY PROTOCOL FOR CRB-401, AN ONGOING PHASE I STUDY OF BB2121 PRODUCT CANDIDATE.BLUEBIRD BIO INC - ENROLLMENT FOR CRB-401 STUDY WILL BE INCREASED BY UP TO 20 PATIENTS, WITH A DOSE RANGE OF 150 TO 450 X 10(6)CAR+ T CELLS.  Full Article

FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy
Wednesday, 23 May 2018 

May 23 (Reuters) - bluebird bio Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY.BLUEBIRD BIO INC - BREAKTHROUGH THERAPY DESIGNATION IS SUPPORTED BY PRELIMINARY DATA FROM ONGOING PHASE 2/3 STARBEAM STUDY (ALD-102).  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED UNDERWRITTEN PUBLIC OFFERING OF 3.2 MILLION SHARES OF ITS COMMON STOCK AT $185 PER SHARE​.  Full Article